TransMedics Group Inc

TransMedics Group (TMDX) is a leader in organ transplant technology and logistics. Although the company reported sales in-line with expectations, profitability was much lower than anticipated due to investments in FDA trials and next-gen technology impacting margins. However, the company reiterated its full-year revenue guidance and indicated that first quarter margins were the trough for the year. Recent data suggests that second quarter revenues should meet expectations, and we expect margins to improve. We believe that TransMedics can continue to gain market share in the organ transplant market and that its execution will enhance going forward.

TransMedics is the market leader in organ transplant logistics with a long runway of growth driven by new products, growing clinical data, and an end market looking for modernization and innovation after years of stagnation. We believe this positions the company well for continued success in a sector that is ripe for transformation.

TransMedics has single-handedly changed the organ transplant process. In sticking with its mission to save lives, the company now owns 22 private jets and is doing roughly 30 organ transplants every single day. As density continues to grow, it becomes more difficult to compete with since the company’s cost per transplant decreases relative to competitors. The market size is the biggest risk here but if TransMedics continues to enable donor after circulatory death (DCD) transplants, it will grow the entire market as fewer organs will be wasted.

TransMedics has established a deep, vertically integrated moat in the DCD liver transplant market, achieving over 60% penetration in the US. The company’s technology has significantly grown this market, and while it faces competition, its logistics infrastructure is improving. Hospitals favor TransMedics due to better post-op results and operational efficiencies, allowing for multiple transplants in a day. Although international expansion may be slow, the potential for revenue growth is substantial, with projections of 4-5x revenue increases as new technologies and kidney indications are developed.

Transmedics (TMDX) was sold following a strong Q1 report that saw the shares nearly double in value. Despite this, competitive dynamics are likely to change later in 2025 and into 2026, leading to the decision to exit the position. The Organ Care System has proven more controversial than expected, with many transplant surgeons questioning whether its value justifies its high cost. Additionally, competition is increasing as OrganOx raised $160mm and XVIVO is starting a liver clinical trial, which will likely pressure market share for TMDX. With shares trading at a high valuation and increasing risks, the exit was deemed prudent.

Transmedics (TMDX) was sold following a strong Q1 report that saw the shares nearly double in value. Despite this, competitive dynamics are likely to change later in 2025 and into 2026, leading to the decision to exit the position. The Organ Care System has proven more controversial than expected, with many transplant surgeons questioning whether its value justifies its high cost. Additionally, competition is increasing, as OrganOx raised $160mm and XVIVO is starting a liver clinical trial, which will likely pressure TMDX's market share. With shares trading at a high valuation and increasing risks, the manager opted to sell.